CA3219657A1 - Quinolinamine compound, preparation method therefor and application thereof in pharmaceuticals - Google Patents

Quinolinamine compound, preparation method therefor and application thereof in pharmaceuticals Download PDF

Info

Publication number
CA3219657A1
CA3219657A1 CA3219657A CA3219657A CA3219657A1 CA 3219657 A1 CA3219657 A1 CA 3219657A1 CA 3219657 A CA3219657 A CA 3219657A CA 3219657 A CA3219657 A CA 3219657A CA 3219657 A1 CA3219657 A1 CA 3219657A1
Authority
CA
Canada
Prior art keywords
general formula
compound
alkyl
group
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3219657A
Other languages
English (en)
French (fr)
Inventor
Fanglong Yang
Minqiang JIA
Huanyu TANG
Yonglei QUE
Feng He
Weikang Tao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Hengrui Pharmaceutical Co Ltd
Jiangsu Hengrui Pharmaceutical Co Ltd
Original Assignee
Shanghai Hengrui Pharmaceutical Co Ltd
Jiangsu Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Hengrui Pharmaceutical Co Ltd, Jiangsu Hengrui Pharmaceutical Co Ltd filed Critical Shanghai Hengrui Pharmaceutical Co Ltd
Publication of CA3219657A1 publication Critical patent/CA3219657A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
CA3219657A 2021-05-27 2022-05-27 Quinolinamine compound, preparation method therefor and application thereof in pharmaceuticals Pending CA3219657A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202110606803.1 2021-05-27
CN202110606803 2021-05-27
CN202110976020.2 2021-08-24
CN202110976020 2021-08-24
PCT/CN2022/095441 WO2022247920A1 (zh) 2021-05-27 2022-05-27 喹啉胺类化合物、其制备方法及其在医药上的应用

Publications (1)

Publication Number Publication Date
CA3219657A1 true CA3219657A1 (en) 2022-12-01

Family

ID=84228425

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3219657A Pending CA3219657A1 (en) 2021-05-27 2022-05-27 Quinolinamine compound, preparation method therefor and application thereof in pharmaceuticals

Country Status (11)

Country Link
US (1) US20240327388A1 (enExample)
EP (1) EP4349831A4 (enExample)
JP (1) JP2024519993A (enExample)
KR (1) KR20240014059A (enExample)
CN (1) CN117222639A (enExample)
AU (1) AU2022283404A1 (enExample)
BR (1) BR112023024741A2 (enExample)
CA (1) CA3219657A1 (enExample)
MX (1) MX2023013972A (enExample)
TW (1) TW202313592A (enExample)
WO (1) WO2022247920A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025538576A (ja) * 2022-11-25 2025-11-28 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 キノリンアミン系化合物の結晶型及びその調製方法
TW202436295A (zh) * 2022-11-25 2024-09-16 大陸商江蘇恒瑞醫藥股份有限公司 喹啉胺類化合物的可藥用鹽、晶型及其製備方法
CN116854634B (zh) * 2023-06-27 2025-12-09 广东药科大学 一种选择性ces2抑制剂、其制备方法及其作为药物的用途
AU2024334442A1 (en) * 2023-08-30 2026-03-05 Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. Compound for regulating activity of microrna-124
CN120698979A (zh) * 2024-03-26 2025-09-26 深圳信立泰药业股份有限公司 一种吲哚类化合物及其制备方法与miR上调应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000015645A1 (fr) * 1998-09-11 2000-03-23 Kyorin Pharmaceutical Co., Ltd. Derives d'esters phosphoniques et leur procede de production
FI2440546T3 (fi) 2009-06-12 2023-03-30 Abivax Ennenaikaisen vanhenemisen ja erityisesti progerian hoitamiseen hyödyllisiä yhdisteitä
JP2011026251A (ja) * 2009-07-27 2011-02-10 Kowa Co ２−アリールアミノキノリン化合物及びこれを有効成分として含有するエリスロポエチン産生促進剤
WO2012037351A1 (en) 2010-09-17 2012-03-22 Glaxosmithkline Llc Compounds
CN104109165A (zh) 2013-04-19 2014-10-22 四川海思科制药有限公司 4,5-二氢-吡唑并[3,4-c]吡啶-2-酮衍生物、其制备方法以及应用
MX382692B (es) 2013-07-05 2025-03-13 Abivax Compuestos bicíclicos útiles para el tratamiento de enfermedades causadas por retrovirus.
EP2974729A1 (en) * 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
EP3059236A1 (en) * 2015-02-23 2016-08-24 Abivax A new quinoline derivative for use in the treatment and prevention of viral infections
PL3429998T3 (pl) 2016-03-18 2022-03-14 Prosynergia S.à.r.l. Sposób wytwarzania pochodnych chinolin-2-ylo-fenyloaminy oraz jej soli
EP3669873A1 (en) * 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use ine the traeatment of inflammation diseases
IL294705A (en) * 2020-01-24 2022-09-01 Univ Princeton Heterocyclic compounds and their uses

Also Published As

Publication number Publication date
KR20240014059A (ko) 2024-01-31
EP4349831A4 (en) 2024-09-04
WO2022247920A9 (zh) 2023-01-05
WO2022247920A1 (zh) 2022-12-01
AU2022283404A1 (en) 2023-11-30
TW202313592A (zh) 2023-04-01
US20240327388A1 (en) 2024-10-03
JP2024519993A (ja) 2024-05-21
BR112023024741A2 (pt) 2024-02-15
EP4349831A1 (en) 2024-04-10
CN117222639A (zh) 2023-12-12
MX2023013972A (es) 2023-12-11

Similar Documents

Publication Publication Date Title
AU2019246753B2 (en) Novel compounds and compositions for inhibition of FASN
EP4349831A1 (en) Quinolinamine compound, preparation method therefor and application thereof in pharmaceuticals
KR101873672B1 (ko) Ｉｄｏ１ 억제제로서 사용하기 위한 피롤리딘-２,５-디온 유도체, 제약 조성물 및 방법
WO2023072297A1 (zh) 含氮的四环化合物、其制备方法及其在医药上的应用
ES2968809T3 (es) Inhibidores de dihidroorotato deshidrogenasa
JP2022524279A (ja) ピリダジン系誘導体阻害剤、その製造方法及び使用
AU2022325367A1 (en) Sulfonamide derivative, preparation method therefor and medical use thereof
CN111484480A (zh) 一种多环类衍生物抑制剂、其制备方法和应用
CA3020541A1 (en) Bet protein degraders
JP7853532B2 (ja) 医学的障害を治療するためのサイクリン依存性キナーゼ阻害化合物
AU2014249192A1 (en) BET bromodomain inhibitors and therapeutic methods using the same
JP2025102917A (ja) 療法に使用するためのｐａｒｐ１４の標的タンパク質分解
JP2016505041A (ja) 置換型ピロロピリミジン化合物、その組成物、およびこれらを用いた治療方法
CN117177971A (zh) 含氮杂环类化合物、其制备方法及其在医药上的应用
CN114907377A (zh) 稠合四环类化合物、其制备方法及其在医药上的应用
CN116669736B (zh) 稠杂环基取代的环己二酰亚胺衍生物、其制备方法及其在医药上的应用
CN115433127A (zh) 喹啉胺类化合物、其制备方法及其在医药上的应用
IL323232A (en) A novel compound and pharmaceutical composition for the prevention or treatment of cancer or tumors containing it
TWI894448B (zh) Ctla-4小分子降解劑及其應用
TW202434590A (zh) 稠合雙環化合物
US20250361239A1 (en) Protein degraders and uses thereof
EA050466B1 (ru) Соединение хинолинаминового ряда, способ его получения и его применение в фармацевтике
CN115835863B (zh) 氧杂氮杂双环类衍生物、其制备方法及其在医药上的应用
CN114478447B (zh) 苯并含氧环类衍生物、其制备方法及其在医药上的应用
EA053325B1 (ru) Сульфонамидное производное, способ его получения и его применение в медицине

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250505

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250505

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260421

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260421